Innate and adaptive immune cells in the joint and systemic immune system

The phrase Innate and adaptive immune cells in the joint and systemic immune system refers to the collective population of leukocytes involved in the pathogenesis of inflammatory arthritides. Innate immune cells, such as synovial macrophages and neutrophils, initiate the inflammatory cascade by producing cytokines like TNF and IL-1 (Firestein & McInnes, Nature, 2017). Adaptive immune cells, including CD4+ T cells and B cells, provide antigen-specific responses and produce autoantibodies like rheumatoid factor and ACPA (StatPearls, 2023). This system encompasses both the local environment of the joint synovium and the systemic immune organs where immune cells are primed and circulated. In diseases like rheumatoid arthritis, the dysregulation of these cells leads to synovial hyperplasia and progressive joint destruction (NIH/NIAMS, 2023). Therapeutic strategies target this system by inhibiting specific cytokines, blocking cell-surface receptors, or modulating intracellular signaling pathways to restore immune tolerance. Common treatments include biologic DMARDs like adalimumab and rituximab, which target TNF-alpha and CD20 respectively, to reduce the inflammatory activity of these cell populations. Monitoring these cells and their products is essential for assessing disease activity and response to therapy in clinical practice.

Other names

Synovial immune systemJoint-infiltrating immune cellsSystemic and local immune effectorsArticular immune environment

Modulation of the immune response through cytokine inhibition, B-cell depletion, T-cell costimulation blockade, or intracellular signaling pathway inhibition.